Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Janus+Kinases%22&type=Subject&filter%5B%5D=collection%3ACTG
/vufind/Search/Results?lookfor=%22Janus+Kinases%22&type=Subject&filter%5B%5D=collection%3ACTG
Search /vufind/Search2/Results?lookfor=%22Janus+Kinases%22&type=Subject&filter%5B%5D=collection%3ACTG
PubPharm (28)
1
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatment : A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment - BOREAS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatment : A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment - BOREAS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatment : A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment - BOREAS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatment : A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment - BOREAS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A Study of TL-895 in Myelofibrosis : A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
28
Aufsätze
28
E-Artikel
28
E-Ressourcen
Zeitschriftentitel
28
WHO International Clinical Trials Registry Plat...
Thema
28
610
28
Phase: Phase 2
28
Recruitment Status: Authorised-recruitment may ...
28
Study Type: Interventional
14
Medical Condition: Primary Or Secondary (Post-P...
12
Medical Condition: Relapsed/Refractory Myelofib...
2
Medical Condition: Primary Or Secondary (Post-P...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2023
12
2022
12
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
28
Englisch
Haven't found what you're looking for?
Wird geladen...